ClinicalTrials.gg
CompletedNCT07319520Updated Jan 7, 2026

Clinical Trial to Evaluate the Efficacy and Safety of DW4902

A Phase 2 interventional study of DW4902 Placebo and DW4902 160mg in Myoma of Uterus, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Oct 2021, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Study summary

A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DW4902 in Patients with Uterine Fibroids.

02

Conditions studied

  • Myoma of Uterus

Browse trials for

03

In context

Myoma

61 studies on the registry are indexed under Myoma; 10 are open to participants now.

This study's enrollment of 71 is below the median of 80 across 45 interventional studies indexed under Myoma.

Browse Myoma studies →

Lead sponsor

Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- [For Subjects Requiring a Run-in Period]

- Screening Visit 1 (Visit 1) Inclusion Criteria

  1. Premenopausal women aged 19 years or older.
  2. Subjects diagnosed with uterine fibroids prior to screening, based on imaging studies.
  3. At least one uterine fibroid with a longest diameter (D1) ≥3 cm confirmed by transvaginal ultrasound at Screening Visit 1.
  4. History or symptoms of heavy menstrual bleeding (HMB) due to uterine fibroids, confirmed prior to screening.
  5. Subject agrees to comply with the following methods and restrictions during the clinical trial.
  6. Subject agrees to use the sanitary products provided during the clinical trial.
  7. Subject has voluntarily consented to participate in this clinical trial and signed the form.

    - Screening Visit 2 (Visit 2) Inclusion Criteria

  8. Prior to Screening Visit 2, the subject has had at least two regular menstrual cycles with menstruation lasting at least three consecutive days in each cycle.
  9. Subject, in the investigator's clinical judgment, is determined to have symptoms of heavy menstrual bleeding (HMB) due to uterine fibroids, requiring medication.

    • Baseline Visit (Visit 3) Inclusion Criteria
  10. During the screening period, the subject has had regular menstrual cycles with menstruation lasting at least three consecutive days in each cycle.
  11. During the screening cycle (Pre-C), a PBAC assessment score of 120 or higher is confirmed.

    • [For Subjects Not Requiring a Run-in Period]
    • Screening Visit 2 (Visit 2) Inclusion Criteria

<!-- -->

  1. Premenopausal women aged 19 years or older.
  2. Subjects diagnosed with uterine fibroids prior to screening via imaging , and at least one uterine fibroid with a longest diameter (D1) ≥3 cm confirmed by transvaginal ultrasound at Screening Visit 2.
  3. Subject, in the investigator's clinical judgment, is determined to have symptoms of heavy menstrual bleeding (HMB) due to uterine fibroids, requiring medication.
  4. Within 3 months prior to screening, the subject has had regular menstrual cycles with menstruation lasting at least three consecutive days in each cycle.
  5. Subject agrees to comply with the following contraceptive methods and restrictions during the clinical trial.
  6. Subject agrees to use the sanitary products provided during the clinical trial.
  7. Subject has voluntarily consented to participate in this clinical trial and signed the informed consent form.

    - Baseline Visit (Visit 3) Inclusion Criteria

  8. During the screening period, the subject has had regular menstrual cycles with menstruation lasting at least three consecutive days in each cycle.
  9. During the screening cycle (Pre-C), PBAC assessment score of 120 or higher is assessed.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from participation in this clinical trial.

  1. A person who is expected to perform the following surgical (procedure) history during the screening period or during the clinical trial period.

    ① Surgery (procedure) history of uterine fibroids within 24 weeks prior to participation in screening.

    : myomectomy, high intensity focused ultrasound, uterine artery embolization etc.

    ② hysterectomy, ovarian resection, endometrial ablation.

    ③ Surgery that may affect gastrointestinal absorption of clinical trial drugs. However, simple appendectomy and hernia surgery can be participated.

  2. As a result of imaging examination at the time of screening (ultrasound, etc.), a person identified as having a gynecological disorder evaluated by the examiner other than uterine myoma.
  3. During the screening period, the following medical history or comorbidities are identified.

    • Endometriosis or symptomatic dominant adenomyosis.

      • Anovulatory bleeding, non-diagnostic abnormal uterine bleeding, or non-diagnostic abnormal genital bleeding.

        • Lower abdominal pain or pelvic inflammatory disease due to trauma or a condition other than uterine fibroids (e.g., irritable bowel syndrome, interstitial cystitis, etc.) within 12 weeks prior to screening participation.

          • Metabolic bone disease, including osteoporosis.

            • Thyroid/parathyroid disease (e.g., hyperthyroidism, hyperparathyroidism), hyperprolactinemia, anorexia nervosa, which contributes to bone mineral density loss, within 24 weeks prior to screening participation.

              • Any , including gynecologic cancer, within 5 years prior to screening participation. However, skin basal cell carcinoma/polarized cell carcinoma/microthyroid papillary carcinoma can participate after successful treatment.

                • Type 1 diabetes or uncontrolled type 2 diabetes.

                  • Major cardiovascular disease within 24 weeks prior to screening.

                    • Severe cardiac disease (heart failure ( class 3 and 4), acute coronary artery disease (unstable angina, acute myocardial infarction), clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter, or other arrhythmias deemed clinically significant by the investigator, and peripheral vascular disease.
                    • Hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, or aortic disease, etc.

                      • Blood disorders. However, those with iron-deficiency anemia are eligible for participation.

                        • thalassemia, sickle cell anemia, folic acid deficiency, coagulopathy. etc. ⑩ Gastrointestinal diseases that may affect the gastrointestinal absorption of the drug at the time of screening ⑪ Active or active at the time of screening ⑫ History of (human immunodeficiency virus) infection ⑬ History of major psychiatric disorders (such as depression, bipolar disorder), or history of substance/alcohol abuse
  4. Subjects exhibiting any of the following test results during the screening period

    • (Hb) \< 8 g/dL (Grade 3 anemia according to ver. 5.0)

      • Bone mineral density test (dual energy x-ray absorptiometry, DXA): Z-score ≤ -1.5 in the lumbar spine, total hip, or femoral neck

        • > 480 msec* (Grade 2 according to CTCAE ver. 5.0)

          • Fridericia's QT correction formula ④ or ALT > 3 x (Grade 2 according to CTCAE ver. 5.0)

            ⑤ Creatinine > 1.5 x ULN (Grade 2 according to CTCAE ver. 5.0)

            ⑥ Uncontrolled hypertension (sitSBP ≥ 160 mmHg or sitDBP ≥ 100 mmHg; Grade 3 according to CTCAE ver. 5.0)

            ⑦ Clinically significant abnormal pathological findings in endometrial

            ⑧ Positive result from PAP smear test

          • according to Bethesda system >NILM (negative for intraepithelial lesion or malignancy)
  5. Pregnant or lactating women during the screening period
  6. Subjects with a history of administering or expected to administer the following medications during the clinical trial:

    ① Use of the following medications within 12 weeks prior to Screening Visit 2, or use of hormonal within 8 weeks prior to Visit 2(including estrogen/progesterone supplements)/hormonal intrauterine device. However, for medroxy progesterone acetate injection depot formulations and Leuprorelin depot 22.5 mg, 30 mg, or 45 mg, administration within 24 weeks prior to Screening Visit 2 must be confirmed.

    GnRH agonists (e.g., Leuprorelin depot 11.25 mg), GnRH antagonists, selective estrogen receptor modulators, progesterone receptor modulators, anti-gonadotropins, gonadotropin-releasing hormones, aromatase inhibitors, anti-estrogens, prolactin inhibitors, spironolactone, etc. However, administration of Leuprorelin depot 3.75 mg within 4 weeks prior to the screening visit constitutes an exclusion criterion.

    • Use of therapeutic agents for metabolic bone diseases within 12 weeks prior to Screening Visit 2.

      • Use of anticoagulants, antiplatelet agents, or low-dose aspirin within 4 weeks prior to Screening Visit 2

        • Use of antifibrinolytic agents within 4 weeks prior to Screening Visit 2 ⑤ Use of analgesics other than ibuprofen during the clinical trial ⑥ Systemic administered for 14 days or more within 12 weeks prior to Screening Visit 2 ⑦ Strong inducers or inhibitors of cytochrome P450 3A4 () within 4 weeks prior to Screening Visit 2 ⑧ Strong inducers or inhibitors of P-glycoprotein (P-gp) within 4 weeks prior to Screening Visit 2
  7. or allergy to the components of the investigational drug.
  8. Hypersensitivity or allergy to hygiene products.
  9. Individuals for whom the gynecological examinations required by the study are considered difficult or impossible to perform.
  10. Individuals who have participated in other clinical trial and received investigational drugs or investigational medical devices within 4 weeks prior to screening.
  11. Individuals otherwise deemed unsuitable for participation in the clinical trial by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo 4 capsules

    Drug: DW4902 Placebo

  • Experimental
    Low-Dose

    DW4902 80mg 2 capsules , Placebo 2 capsules

    Drug: DW4902 160mg

  • Experimental
    Medium-Dose

    DW4902 80mg 3 capsules , Placebo 1 capsules

    Drug: DW4902 240mg

  • Experimental
    High-Dose

    DW4902 80mg 4 capsules

    Drug: DW4902 320mg

Interventions

  • DrugDW4902 Placebo

    Starting from the Baseline Visit (Visit 3), administer orally once daily at a dose of 4 capsules before meals for 12 weeks. (Placebo 4 capsules)

  • DrugDW4902 160mg

    Starting from the Baseline Visit (Visit 3), administer orally once daily at a dose of 4 capsules before meals for 12 weeks.. (DW4902 80mg 2 capsules , Placebo 2 capsules)

  • DrugDW4902 240mg

    Starting from the Baseline Visit (Visit 3), administer orally once daily at a dose of 4 capsules before meals for 12 weeks.. (DW4902 80mg 3 capsules , Placebo 1 capsules)

  • DrugDW4902 320mg

    Starting from the Baseline Visit (Visit 3), administer orally once daily at a dose of 4 capsules before meals for 12 weeks.. (DW4902 80mg 4 capsules)

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with a total PBAC score

    Percentage of subjects with a total PBAC score of less than 10 points in the 6 to 12 week period since the baseline visit

    Time frame: 6 to 12 week period since the baseline visit

Secondary outcomes

  1. Percentage of subjects with a total PBAC score

    Percentage of subjects with a total PBAC score of less than 10 points in the 2 to 6 week period since the baseline visit.

    Time frame: 2 to 6 week period since the baseline visit.

  2. Percentage of subjects with a total PBAC score

    Percentage of subjects with a total PBAC score of less than 10 points in the 8 to 12 week period since the baseline visit.

    Time frame: 8 to 12 week period since the baseline visit.

  3. Percentage of subjects with a total PBAC score

    Percentage of subjects with a total PBAC score of less than 10 points in the previous recent menstrual cycle, as of the 12-week visit point after dosing

    Time frame: 12-week visit point after dosing

  4. Percentage of subjects for amenorrhea

    Percentage of subjects for amenorrhea during the 6 to 12 week period after the baseline visit

    Time frame: 6 to 12 week period after the baseline visit

  5. Percentage of subjects for amenorrhea

    Percentage of subjects for amenorrhea during the 2 to 6 week period after the baseline visit

    Time frame: 2 to 6 week period after the baseline visit

  6. Changes in hemoglobin levels (g/dL)

    Changes in hemoglobin levels (g/dL) at 8 weeks and 12 weeks after dosing compared to baseline visits

    Time frame: 8 weeks and 12 weeks after dosing compared to baseline visits

  7. The proportion of subjects whose hemoglobin level increased by >2 g/dL

    Among subjects with a hemoglobin level ≤10.5 g/dL at the baseline visit, the proportion of subjects whose hemoglobin level increased by \>2 g/dL at the 8-week and 12-week visits compared to the baseline visit

    Time frame: 8 week and 12 week visits compared to the baseline visit

  8. Changes and rates of change in uterine fibroid size

    Changes and rates of change in uterine fibroid size at the 12-week visit after dosing compared to the baseline visit

    Time frame: 12 week visit after dosing compared to the baseline visit

  9. Changes and rates of change in uterine size

    Changes and rates of change in uterine size at the 12-week visit after dosing compared to the baseline visit

    Time frame: 12 week visit after dosing compared to the baseline visit

  10. The proportion of subjects with a uterine fibroid-associated peak NRS pain score

    Among subjects with a uterine fibroid-associated peak NRS pain score of ≥4 during the menstrual cycle (Pre-C) of the screening period, the proportion of subjects with a uterine fibroid-associated peak NRS pain score of ≤1 during the 6 to 12 week period after the baseline visit

    Time frame: 6 to 12 week period after the baseline visit

07

Study locations

1 site
  • Asan Medical Center
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Nov 2024, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 6, 2026
StartActual
Oct 6, 2021
Primary completionActual
Nov 11, 2024
CompletionActual
Nov 11, 2024
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07319520
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Oct 6, 2021
Primary completion
Nov 11, 2024
Completion
Nov 11, 2024
Last update
Jan 7, 2026

Study contacts

Sunghoon Kim
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion